This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Clinical Trials
Nacuity
Safety and efficacy of NP1-001 tablets for retinitis pigmentosa associated with Usher syndrome. This study will examine the safety and potential impact of a new treatment in slowing down retinal changes associated with retinitis pigmentosa (RP) in people with Usher syndrome.
Overview
This study will explore the safety and potential effect of NPI-001 therapy in people with RP associated with Usher syndrome. There will be a treatment group and a placebo group being compared over time.
The study will look at retinal sensitivity assessed by microperimetry from baseline, as well as a range of features across various retinal imaging modalities.
- Principal Investigator
Dr Jonathan Ruddle
This study will explore the safety and potential effect of NPI-001 therapy in people with RP associated with Usher syndrome. There will be a treatment group and a placebo group being compared over time.
The study will look at retinal sensitivity assessed by microperimetry from baseline, as well as a range of features across various retinal imaging modalities.
- Principal Investigator
Learn more
View this study at ClinicalTrials.gov
This international database listing provides more detailed information about this study.